Cargando…

Regulatory filing strategy for generic mesalazine modified release formulations

Detalles Bibliográficos
Autor principal:	Gupta, Sandeep K.
Formato:	Texto
Lenguaje:	English
Publicado:	Medknow Publications 2011
Materias:	Letters to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3081473/ https://www.ncbi.nlm.nih.gov/pubmed/21572669 http://dx.doi.org/10.4103/0253-7613.77386

Ejemplares similares

Azathioprine-induced Myelotoxicity After Switching Mesalazine Compound
por: Barnhoorn, Marieke C, et al.
Publicado: (2021)

A comprehensive study on regulatory requirements for development and filing of generic drugs globally
por: Handoo, Shweta, et al.
Publicado: (2012)

Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation
por: Tamura, Satoshi, et al.
Publicado: (2020)

Therapeutic Efficacy of pH-Dependent Release Formulation of Mesalazine on Active Ulcerative Colitis Resistant to Time-Dependent Release Formulation: Analysis of Fecal Calprotectin Concentration
por: Kawashima, Kousaku, et al.
Publicado: (2014)

Generic Substitution
por: Walley, T.
Publicado: (1993)

Generic Substitution
por: Cheng, Tsung O
Publicado: (1993)

Sampling times and genotyping concerns in bioequivalence evaluation of branded and generic formulations
por: Zhao, Xiao-Ying, et al.
Publicado: (2013)

Efficacy of oral prolonged‐release mesalazine in moderately active ulcerative colitis
por: Paridaens, Kristine, et al.
Publicado: (2023)

More Vigilance on Generic Drugs are Necessary
por: John, Mathew
Publicado: (2020)

Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance Part 2: Dissolution of Montelukast Sodium and Mesalazine Formulations
por: Martir, J., et al.
Publicado: (2020)

Clomipramine, clomiphene, and generic drug-dispensing errors
por: Bavle, Amar, et al.
Publicado: (2016)

Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine
por: Prenzler, Anne, et al.
Publicado: (2011)

Mesalazine-induced renal calculi
por: Jacobsson, Henrik, et al.
Publicado: (2013)

Myocarditis Related to the Use of Mesalazine
por: Kyriakou, Michaela, et al.
Publicado: (2023)

Hidden Paradoxes in Generic Drug Substitution Affecting Pharmacotherapy
por: Sapone, A., et al.
Publicado: (2009)

Upstream solutions for price-gouging on critical generic medicines
por: Houston, Adam R., et al.
Publicado: (2016)

Encapsulation of Hydrocortisone and Mesalazine in Zein Microparticles
por: Lau, Esther T. L., et al.
Publicado: (2013)

Bipolymeric Pectin Millibeads Doped with Functional Polymers as Matrices for the Controlled and Targeted Release of Mesalazine
por: Wójcik-Pastuszka, Dorota, et al.
Publicado: (2020)

Efficacy of mesalazine in children with moderate to severe alopecia areata: case series of 18 patients()
por: Vivian, Analú, et al.
Publicado: (2023)

Generic antibiotic industries: Challenges and implied strategies with regulatory perspectives
por: Venkatesh, M., et al.
Publicado: (2011)

Generic Statins and Angiotensin Receptor Blockers: Are They Really Useful in Ebola?
por: Wiwanitkit, Viroj
Publicado: (2016)

Reply to the editorial – “Only generics (drugs/names): Is India ready?”
por: Sahay, Rakesh Kumar, et al.
Publicado: (2016)

Effect of Excipients on the Quality of Drug Formulation and Immediate Release of Generic Metformin HCl Tablets
por: Arafat, Mosab, et al.
Publicado: (2023)

Randomised controlled trial of mesalazine in IBS
por: Barbara, Giovanni, et al.
Publicado: (2016)

The file drawer effect: A call for meticulous methodology and tolerance for non-significant results
por: Nagarajan, Priscilla Joys, et al.
Publicado: (2017)

First Multicenter Study of Modified Release Phosphatidylcholine “LT-02” in Ulcerative Colitis: A Randomized, Placebo-Controlled Trial in Mesalazine-Refractory Courses
por: Karner, Max, et al.
Publicado: (2014)

In Vitro-In Vivo Correlation Evaluation of Generic Alfuzosin Modified Release Tablets
por: Sanki, Utpal Kumar, et al.
Publicado: (2012)

Psychoeducation: Need for an Alternative Generic, Destigmatized, and Patient-Friendly Term in Clinical Practice
por: Manjunatha, Narayana, et al.
Publicado: (2021)

Immediate switching from a chrono to an extended-release formulation of divalproex sodium: A two-part study in patients with controlled epilepsy
por: Shukla, Rakesh, et al.
Publicado: (2008)

Colorectal Cancer Chemoprevention by Mesalazine and Its Derivatives
por: Stolfi, Carmine, et al.
Publicado: (2012)

Mesalazine-induced myocarditis: a case report
por: Radhakrishnan, Shiva T., et al.
Publicado: (2018)

Repurposing mesalazine against cardiac fibrosis in vitro
por: Hoffmann, Maximilian, et al.
Publicado: (2020)

Mesalazine-induced myopericarditis: a case report
por: Shergill, Simran
Publicado: (2020)

Analysis of clinical characteristics of mesalazine-induced cardiotoxicity
por: Chen, Junyu, et al.
Publicado: (2022)

Nanoparticles Obtained from Zein for Encapsulation of Mesalazine
por: Lima, Izabela Borges C., et al.
Publicado: (2022)

Mesalazine-induced myopericarditis: a case series
por: Andrei, Valentina, et al.
Publicado: (2023)

Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
por: Yagisawa, Keiji, et al.
Publicado: (2019)

Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics?
por: Gupta, Ranjan
Publicado: (2020)

Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer
por: Geissler, J, et al.
Publicado: (2016)

Generic amyloid fibrillation of TMEM106B in patient with Parkinson’s disease dementia and normal elders
por: Fan, Yun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_34ob167p2b7ubko642egduejgf